CHEK2 and cancer: We analyzed electronic health record (EHR) in two population-based cohorts (UK Biobank (UKBB) and Geisinger MyCode) to estimate the prevalence, age-dependent penetrance, cancer risk and survival of CHEK2 pathogenic heterozygotes compared to controls.